

UNAIDS/WHO WORKING GROUP ON
GLOBAL HIV/AIDS AND STI SURVEILLANCE

FIND & WHO WORKING GROUP ON HIV INCIDENCE ASSAYS MEETING REPORT

20–26 FEBRUARY 2016
BOSTON, MA, USA



UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance

Global surveillance of HIV and sexually transmitted infections is a joint effort of the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS). The UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance, initiated in November 1996, is the main coordination and implementation mechanism for UNAIDS and WHO to compile the best information available and to improve the quality of data needed for informed decision-making and planning at the national, regional and global levels.



**World Health
Organization**

HIV/AIDS Programme

**UNAIDS/WHO WORKING GROUP ON GLOBAL
HIV/AIDS AND STI SURVEILLANCE**

**FIND & WHO WORKING GROUP ON HIV
INCIDENCE ASSAYS MEETING REPORT**

**20–26 FEBRUARY 2016
BOSTON, MA, USA**

© World Health Organization 2017

WHO/HIV/2017.04

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization..

Suggested citation. Foundation for Innovative New Diagnostics, WHO Working Group on HIV Incidence Assays. Meeting report, Boston, MA, USA, 20–26 February 2016. Geneva: World Health Organization; 2017 (WHO/HIV/2017.04). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts [or give name of group] and does not necessarily represent the decisions or the policies of WHO.

This publication contains the report of the WHO Incidence Working Group and] does not necessarily represent the decisions or policies of WHO.

Layout by LSI

CONTENTS

ABBREVIATIONS	iv
1. BACKGROUND	1
2. METHODS OF WORK	2
3. ALIGNMENT ON CRITICAL ASSAY CHARACTERISTICS	3
3.1 CEPHIA and the CDC	3
3.2 Johns Hopkins University	4
3.3 Time since infection specimen dating	4
3.3 MDRI: the differences and how to resolve them	5
3.5 Optimizing the LAg + viral load recent infection testing algorithm – implications for sample sizes	6
3.6 ARV medicine testing component in recent infection testing algorithms	8
3.7 Real-world experience with LAg	9
3.8 External Quality Assurance Program Oversight Laboratory for incidence assays	10
3.9 Update on the case-based surveillance meeting	10
3.10 New assay validation by CEPHIA: Geenius™, ARCHITECT®, Glasgow-modified Genscreen™ HIV-1/2 Version 2 and IDE-V3	11
3.11 Update on the development of rapid assays and the potential applications and advantages	12
4. DISCUSSION AT THE END OF DAY 1	14
5. TARGET PRODUCT PROFILES FOR HIV INCIDENCE ASSAYS	15
5.1 New target product profiles for HIV incidence assays (presented by Peter Dailey, FIND)	15
5.2 Discussion of target product profiles	16
5.2.1 Test performance characteristics	16
5.2.2 Time the analyte is stable in specimen storage format	17
5.2.3 Specimen types	18
5.2.4 Recognition of HIV subtypes and circulating recombinant forms	18
5.2.5 Target test cost	18
5.2.6 Supplementary tests	18
5.2.7 Time from assay start until the results are available	18
6. UPDATED MARKET ASSESSMENT FOR HIV INCIDENCE ASSAYS AND BIOMARKERS IN THE PIPELINE	20
6.1 Updated market assessment (presented by Charles Morrison and Rick Homan, FHI 360)	20
6.2 Updated market assessment: discussion	23
6.3 Update on biomarkers in the pipeline	23
7. CONCLUSIONS AND NEXT STEPS	25
REFERENCES	26
ANNEX 1. MEETING PROGRAMME	28
ANNEX 2. LIST OF PARTICIPANTS	30

ABBREVIATIONS

ART	antiretroviral therapy
ARV	antiretroviral
CDC	United States Centers for Disease Prevention and Control
CEPHIA	Consortium for the Evaluation of the Performance of HIV Incidence Assays
CI	confidence interval
DBS	dried blood spot
DREAMS	Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe women
FIND	Foundation for Innovative New Diagnostics
FRR	false recent rate
Global Fund	Global Fund to Fight AIDS, Tuberculosis and Malaria
HPTN	HIV Prevention Trials Network
IDE	immunodominant epitope
LA_g	limiting antigen
MDRI	mean duration of recent infection
PBS	phosphate-buffered saline
PCR	polymerase chain reaction
PEPFAR	United States President's Emergency Plan for AIDS Relief
PrEP	pre-exposure prophylaxis
RT-PCR	reverse-transcription polymerase chain reaction
SACEMA	South African Centre for Epidemiological Modelling and Analysis
SHIMS	Swaziland HIV Incidence Measurement Survey

1. BACKGROUND

In 2008, WHO established a Technical HIV Incidence Assay Working Group to examine the issues and challenges involved in estimating HIV incidence using assays. This Group comprises epidemiologists, laboratory specialists and public health officials and has worked to standardize the terms in the fields of assay calibration and validation. Several meetings to advance the agenda have been held, and copies of the reports are available on the Working Group web page (www.who.int/diagnostics_laboratory/links/hiv_incidence_assay/en).

These meetings have been successful in bringing together a wide group of assay users, especially from countries affected by the HIV epidemic that may consider using HIV incidence assays in the future, together with experts in applying laboratory-based methods for estimating HIV incidence. The importance of HIV incidence as a key indicator of the success or failure of national HIV programmes has been highlighted, and health ministries clearly need to be aware of the complexities in producing estimates based on data generated by the currently available assays.

In collaboration with the United States Centers for Disease Control and Prevention (CDC), the Working Group produced a guidance document on how to estimate HIV incidence at the population level using HIV incidence assays in cross-sectional studies (1). In 2010, the Bill & Melinda Gates Foundation adjudicated a grant proposal to Public Health England and the Blood Systems Research Institute to continue laboratory work on existing HIV incidence assays. The Consortium for the Evaluation of the Performance of HIV Incidence Assays (CEPHIA) was established, which aims to validate existing and future HIV incidence assays, compare results from existing assays with direct incidence measurements and identify the key parameters to enable assay results to be interpreted correctly.

The Working Group last convened in October 2014 in Barcelona, Spain; this was funded by WHO, the CDC, CEPHIA and UNAIDS (2). Following this meeting, a technical update was published for the application of HIV incidence assays for surveillance (3), which was also incorporated into the new guidelines for monitoring the impact of the HIV epidemic using population-based surveys (4).

The purpose of the 2016 meeting of the Working Group was to convene a group of key opinion leaders in the field to discuss critical issues outstanding after the previous Working Group meeting. The main objectives of this meeting were:

- to obtain consensus on the mean duration of recent infection (MDRI) for the CDC-derived limiting antigen (LAG) assays (from Sedia Biosciences Corporation and Maxim Biomedical) and variability among HIV subtypes;
- to present the performance characteristics of five further incidence assays studied as part of the CEPHIA evaluation;
- to present the evaluation of recent infection testing algorithms including testing for viral load and for antiretroviral (ARV) medicines;
- to release the revised version of the sample size calculation tool by the developer, recommended by WHO (5);
- to determine methods for qualifying new kit lots made by commercial partners to ensure LAG quality management systems during manufacturing processes;
- to establish a proficiency testing programme for the LAG assay that may be expanded to other assays as the need for external quality assurance is demonstrated; and
- to obtain consensus on target product profiles for tests for recent HIV infection.

The 2016 Working Group meeting in Boston was funded by UNAIDS, the Foundation for Innovative New Diagnostics (FIND) and WHO.

2. METHODS OF WORK

HIV incidence and mortality remain important indicators for the Sustainable Development Goals and are used as target measures, especially by the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) and the United States President's Emergency Plan for AIDS Relief (PEPFAR).

The current role of the Working Group is:

- to review and document the calibration, performance and validation of HIV incidence assays;
- to create a catalogue of studies reporting on assay validation and calibration;
- to define the assay development pathway and target product profiles; and
- to obtain consensus on statistical issues and terms.

Since publication, the guidance on how to apply incidence assays has since been accompanied by two technical updates (3).

The critical path to improve HIV incidence testing incorporates market, technical and regulatory issues and requires developing normative guidance, advocacy and support. Market issues include the need for a reliable commercial supplier of incidence assays; technical issues include the need for specimens to standardize the calibration and validation of assays; regulatory issues

include identifying and executing a clear regulatory path to independent validation and approved use in the market. WHO/UNAIDS will need to develop updated guidance to be adopted by the HIV community, with dedicated individuals supporting new users.

Understanding of the characteristics and limitations of HIV incidence assays has improved, including the need for large sample sizes in low-incidence areas. However, more work is needed to be able to expand their use to produce subnational estimates and estimates for key populations. Challenges include the scaling up of antiretroviral therapy (ART) and whether this will require ARV testing in addition to viral load in a recent infection testing algorithm. The effect of early or discontinued ART or a history of pre-exposure prophylaxis (PrEP) use is still being evaluated, but recent studies demonstrate that these can affect recency assays, such as slowing antibody avidity maturation. In addition, a local estimate of the false recent ratio (FRR) is required, which will become increasingly difficult with widespread ART use. The FRR varies by HIV subtype, being especially high among people with subtype D and is unknown for subtypes CRF02_AG and CRF01_AE. Following these outstanding issues, and specifically in the context of the new "treat all" guidelines, recommendations on best practices in the context of tests for recent infection are needed.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_26542

